Table 5

Ongoing RCT on prevention of AF with omega-3 fatty acids

Study	Country	Study population	No of patients	PUFA and dosage	Primary endpoint	Follow-up	Status (last update time)
NCT00508248	UK	Persistent AF Post-cardioversion	180	1 g/day PUFA (EPA:DHA 1.2:1) 4 week before and 6 months after cardioversion	First recurrence of atrial fibrillation/flutter lasting more than 10 min	6 Months	Recruiting (26 July 2007)
NCT00552084	USA	Paroxysmal AF	450	4 g/day PUFA for 24 weeks (EPA:DHA 1.24:1)	Recurrent AF/AFL	24 Weeks	Recruiting; Estimated completion November 2012 (14 July 2009)
NCT00791089	USA	Paroxysmal and persistent AF undergoing ablation	200	4 g/day PUFA (EPA+DHA) 4 weeks before and 3 months after ablation	Freedom from atrial arrhythmias without antiarrhythmic drug therapy	6 Months	Recruiting; Estimated completion October, 2010 (13 November 2008)
NCT00841451	USA	Paroxysmal and persistent AF undergoing pulmonary vein isolation	NA	PUFA (EPA+DHA)	Early recurrent AF post-ablation	NA	NA (1 October 2010)
NCT01175330	Russia	Post-CABG, SR	150	Intravenous PUFA (1 ml/kg per day) for 7 days post-surgery period (the first infusion beginning in operative period)	Freedom of AF or other atrial arrhythmias	2 Years	Recruiting; Estimated completion August 2012 (5 August 2010)
FORomegaARD NCT00597220	Argentina	Symptomatic paroxysmal or persistent AF Post-cardioversion	1400	1 g/day PUFA (EPA+DHA)	Survival free of AF	12 Months	Recruiting; Estimated completion July 2010 (30 July 2008)
OPERA NCT00970489	USA, Italy and Argentina	Post-cardiac surgery, SR	1516	8 g/day PUFA 2–4 days before cardiac surgery, 2 g/day for 10 days, or until discharge	Postoperative AF within 10 days post-surgery or discharge	10 Days or until discharge	Recruiting; Estimated completion May 2011 (29 September 2010)
AFFORD NCT01235130	Canada	Paroxysmal or persistent AF in whom a rhythm control strategy is planned	332	2.4 g/day PUFA	The time to first relapse of AF lasting longer than 30 s during the follow-up period	67 Weeks	Recruiting; Estimated completion July 2011 (4 November 2010)

AF, atrial fibrillation; AFFORD, Multi-center Study to Evaluate the Effect of N-3 Fatty Acids (OMEGA-3) on Arrhythmia Recurrence in Atrial Fibrillation; AFL, atrial flutter; CABG, coronary artery bypass graft surgery; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; FORomegaARD, Fish Oil Research with ω-3 for Atrial fibrillation Recurrence Delaying; NA, not available; OPERA, Omega-3 Fatty Acids for Prevention of PostOperative Atrial Fibrillation; PUFA, omega-3 polyunsaturated fatty acids; RCT, randomised controlled trial; SR, sinus rhythm.